Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107640905> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3107640905 endingPage "172" @default.
- W3107640905 startingPage "164" @default.
- W3107640905 abstract "Introduction Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A with and without inhibitors. Management of breakthrough bleeding in patients with inhibitors on emicizumab involves episodic treatment with bypassing agents (BPA), activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa). Thrombotic events and thrombotic microangiopathy were reported when patients on emicizumab received concomitant aPCC at relatively high doses yet such events were not reported with rFVIIa. We studied the effect of spiking various concentrations of BPA on plasma taken from patients on emicizumab. Material and methods Eleven patients with severe haemophilia A with inhibitors who are on emicizumab were recruited to participate. Blood samples drawn from patients were spiked in vitro with varying concentrations of aPCC and rFVIIa. All samples were tested utilizing global haemostasis assays, thromboelastography and thrombin generation assay. Results Thrombin generation increased with higher concentrations of spiked BPA with a normalized endogenous thrombin potential at a concentration of 0.05 IU/ml and 4 mcg/ml for aPCC and rFVIIa, respectively. Concentrations of aPCC in the range of licensed dosing led to excessive thrombin generation. Thromboelastography was not sufficiently sensitive. Conclusion Due to the known thrombotic complications when emicizumab is used in conjunction with aPCC, there has been a large-scale abandonment of the use of aPCC in patients on emicizumab. However, it is possible that aPCC can be used safely with emicizumab albeit with lower doses than are typically prescribed. It would be important to test this hypothesis in a clinical study." @default.
- W3107640905 created "2020-12-07" @default.
- W3107640905 creator A5018987356 @default.
- W3107640905 creator A5038204903 @default.
- W3107640905 creator A5048561431 @default.
- W3107640905 creator A5050451275 @default.
- W3107640905 creator A5060869564 @default.
- W3107640905 creator A5089807659 @default.
- W3107640905 date "2020-11-27" @default.
- W3107640905 modified "2023-09-23" @default.
- W3107640905 title "Comparison of bypassing agents in patients on emicizumab using global hemostasis assays" @default.
- W3107640905 cites W1985574423 @default.
- W3107640905 cites W2734287351 @default.
- W3107640905 cites W2793763904 @default.
- W3107640905 cites W2805799263 @default.
- W3107640905 cites W2808215790 @default.
- W3107640905 cites W2936143155 @default.
- W3107640905 cites W2945243639 @default.
- W3107640905 cites W2958765768 @default.
- W3107640905 cites W2965331692 @default.
- W3107640905 cites W2965671309 @default.
- W3107640905 cites W2980900975 @default.
- W3107640905 doi "https://doi.org/10.1111/hae.14213" @default.
- W3107640905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33245833" @default.
- W3107640905 hasPublicationYear "2020" @default.
- W3107640905 type Work @default.
- W3107640905 sameAs 3107640905 @default.
- W3107640905 citedByCount "14" @default.
- W3107640905 countsByYear W31076409052021 @default.
- W3107640905 countsByYear W31076409052022 @default.
- W3107640905 countsByYear W31076409052023 @default.
- W3107640905 crossrefType "journal-article" @default.
- W3107640905 hasAuthorship W3107640905A5018987356 @default.
- W3107640905 hasAuthorship W3107640905A5038204903 @default.
- W3107640905 hasAuthorship W3107640905A5048561431 @default.
- W3107640905 hasAuthorship W3107640905A5050451275 @default.
- W3107640905 hasAuthorship W3107640905A5060869564 @default.
- W3107640905 hasAuthorship W3107640905A5089807659 @default.
- W3107640905 hasConcept C126322002 @default.
- W3107640905 hasConcept C2778382381 @default.
- W3107640905 hasConcept C2778589496 @default.
- W3107640905 hasConcept C2910877098 @default.
- W3107640905 hasConcept C71924100 @default.
- W3107640905 hasConceptScore W3107640905C126322002 @default.
- W3107640905 hasConceptScore W3107640905C2778382381 @default.
- W3107640905 hasConceptScore W3107640905C2778589496 @default.
- W3107640905 hasConceptScore W3107640905C2910877098 @default.
- W3107640905 hasConceptScore W3107640905C71924100 @default.
- W3107640905 hasFunder F4320332193 @default.
- W3107640905 hasIssue "1" @default.
- W3107640905 hasLocation W31076409051 @default.
- W3107640905 hasOpenAccess W3107640905 @default.
- W3107640905 hasPrimaryLocation W31076409051 @default.
- W3107640905 hasRelatedWork W2089799535 @default.
- W3107640905 hasRelatedWork W2172448675 @default.
- W3107640905 hasRelatedWork W2373393772 @default.
- W3107640905 hasRelatedWork W2375557308 @default.
- W3107640905 hasRelatedWork W2387503964 @default.
- W3107640905 hasRelatedWork W2406194191 @default.
- W3107640905 hasRelatedWork W2412256898 @default.
- W3107640905 hasRelatedWork W2463038551 @default.
- W3107640905 hasRelatedWork W4297982189 @default.
- W3107640905 hasRelatedWork W4362521366 @default.
- W3107640905 hasVolume "27" @default.
- W3107640905 isParatext "false" @default.
- W3107640905 isRetracted "false" @default.
- W3107640905 magId "3107640905" @default.
- W3107640905 workType "article" @default.